<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Miltefosine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Miltefosine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Miltefosine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="94960" href="/d/html/94960.html" rel="external">see "Miltefosine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="109303" href="/d/html/109303.html" rel="external">see "Miltefosine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F24249383"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Embryo-fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Miltefosine is contraindicated in pregnancy. Based on animal data, miltefosine may cause fetal harm. Verify pregnancy status prior to initiating miltefosine. To prevent pregnancy, patients of reproductive potential should use effective contraception during treatment and for 5 months after the last dose.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46502570"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Impavido</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F22903466"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiparasitic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F22903483"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b4dbf217-40fa-43b0-adc0-ae96f39c346e">Free-living ameba infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Free-living ameba infection (granulomatous amebic encephalitis [<i>Acanthamoeba</i> spp., <i>B. mandrillaris</i>] and primary amebic meningoencephalitis [<i>N. fowleri</i>]) (off-label use):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&lt;45 kg: 50 mg twice daily (CDC 2019b; Drugs for Parasitic Infections 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">≥45 kg: 50 mg 3 times daily (CDC 2019b; Drugs for Parasitic Infections 2013).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed727c2e-50ad-4916-9de0-8aa740ea0c6a">Leishmaniasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis (cutaneous, mucosal, visceral): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monotherapy:</i>
<b>Note:</b> Efficacy is species and locale dependent. For visceral leishmaniasis, reserve use for patients who are unable to use preferred therapy (Drugs for Parasitic Infections 2013; HHS [OI adult 2021]; IDSA/ASTMH [Aronson 2016]).</p>
<p style="text-indent:-2em;margin-left:6em;">30 to 44 kg: <b>Oral:</b> 50 mg twice daily for 28 days.</p>
<p style="text-indent:-2em;margin-left:6em;">≥45 kg: <b>Oral:</b> 50 mg 3 times daily for 28 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy (off-label):</i>
<b>Note:</b> For patients with HIV and visceral leishmaniasis acquired in East Africa or Southeast Asia (WHO 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>50 mg twice daily in combination with liposomal amphotericin B. Duration of miltefosine is 14 days for patients in Southeast Asia and 28 days for patients in East Africa (Abongomera 2018; Burza 2022; Diro 2019; Mahajan 2015; WHO 2022).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990150"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987482"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F24255958"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F22903482"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="109303" href="/d/html/109303.html" rel="external">see "Miltefosine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed727c2e-50ad-4916-9de0-8aa740ea0c6a">Leishmaniasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis:</b> Children ≥12 years and Adolescents weighing ≥30 kg: Oral: Cutaneous, mucosal, visceral leishmaniasis: <b>Note:</b> Efficacy is species- and locale-dependent.</p>
<p style="text-indent:-2em;margin-left:4em;">30 to 44 kg: 50 mg twice daily for 28 days.</p>
<p style="text-indent:-2em;margin-left:4em;">≥45 kg: 50 mg 3 times daily 28 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="232aa687-9f96-49ef-b627-13a5140272e7">Naegleria fowleri infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Naegleria fowleri</i> infection (free-living ameba):</b> Very limited data available; efficacy results variable; <b>Note:</b> Due to the poor prognosis of infection and lack of successful treatment options, expert recommendations suggest adding miltefosine as a component of treatment regimen (CDC 2020; Cope 2016; Linam 2015; <i>Red Book</i> [AAP 2018]):</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;45 kg: 50 mg twice daily for 28 days (CDC 2020; Linam 2015); an 8-year-old (weight not reported) received 50 mg 3 times daily (Cope 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">≥45 kg: 50 mg 3 times daily for 28 days (Cope 2016; Linam 2015).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130117"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51130118"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F22906298"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (8% to 11%), decreased appetite (11% to 23%), diarrhea (8% to 20%), motion sickness (29%), nausea (36% to 42%), vomiting (5% to 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Asthenospermia, decreased ejaculate volume, oligospermia, scrotal pain (tenderness), spermatozoa disorder (reduction in sperm morphology)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased platelet count (&lt;150,000: 62%; &lt;50,000: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (&lt;3 × ULN: 94%; ≥3 × ULN: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (5% to 13%), headache (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (≥1.5 × above baseline: 10% to 25%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (&lt;2%), ecthyma (&lt;2%), pruritus (5% to 6%), pyoderma (&lt;2%), skin rash (&lt;2%), Stevens-Johnson syndrome (&lt;2%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (&lt;2%), constipation (&lt;2%), dysphagia (&lt;2%), flatulence (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dry ejaculation, epididymitis, testicular pain (&lt;2%), testicular swelling (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;2%), lymphadenopathy (&lt;2%), lymphangitis (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (3%), fatigue (&lt;2%), malaise (3%), paresthesia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiology: Edema, peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Melena</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p></div>
<div class="block coi drugH1Div" id="F22903471"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to miltefosine or any component of the formulation; Sjogren-Larsson syndrome; pregnancy</p></div>
<div class="block war drugH1Div" id="F22903472"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Stevens-Johnson syndrome has been reported; discontinue miltefosine if an exfoliative or bullous rash occurs during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: Nausea, vomiting and diarrhea may occur with use; administer with food to decrease GI effects. Ensure adequate fluid intake during therapy to prevent dehydration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic toxicity: Thrombocytopenia has been reported during therapy for visceral leishmaniasis; monitor platelet count during therapy in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Increased liver transaminases and bilirubin have been reported during therapy for visceral leishmaniasis. Assess ALT, AST, and bilirubin during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: May increase serum creatinine. Assess kidney function weekly while on therapy and for 4 weeks after the end of therapy.</p></div>
<div class="block prod-avail drugH1Div" id="F22815381"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Ordering and distribution information may be obtained by calling 1-908-635-2326 or visiting http://www.impavido.com/order-page.</p></div>
<div class="block foc drugH1Div" id="F22904239"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Impavido: 50 mg</p></div>
<div class="block geq drugH1Div" id="F46502569"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46817110"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Impavido Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $713.57</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F22903463"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Miltefosine may be ordered directly from Profunda by any licensed pharmacy; it is not available through wholesalers. For ordering and distribution information call 1-908-635-2326 or visit http://www.impavido.com/order-page.</p></div>
<div class="block adm drugH1Div" id="F22903486"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Oral: Administer with food to decrease GI distress. Twice daily dosing should be administered with breakfast and dinner; 3 times daily dosing with breakfast, lunch, and dinner.</p></div>
<div class="block admp drugH1Div" id="F52614223"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Oral: Administer with food to decrease GI distress. Twice-daily dosing should be administered with breakfast and dinner; 3-times daily dosing with breakfast, lunch, and dinner. </p></div>
<div class="block hazard drugH1Div" id="F51765909"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Miltefosine may cause teratogenicity and reproductive toxicity. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>
<div class="block meg drugH1Div" id="F24151847"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;">Impavido: <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FUCM390972.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9BK5et6GehFK9IioulPK5WHeLlvW27hVqpt29VHRKVRA%3D%3D&amp;TOPIC_ID=91793" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM390972.pdf</a></p></div>
<div class="block use drugH1Div" id="F22903468"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis:</b> Treatment of visceral (caused by <i>Leishmania donovani</i>), cutaneous (caused by <i>L. braziliensis</i>, <i>L. guyanensis</i>, and <i>L. panamensis</i>), and mucosal leishmaniasis (caused by <i>L. braziliensis</i>) in adults and adolescents ≥12 years of age weighing ≥30 kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Efficacy of miltefosine in the treatment of other <i>Leishmania</i> species has not been evaluated; there may be geographic variation in clinical response of the same <i>Leishmania</i> species to miltefosine.</p></div>
<div class="block off-label drugH1Div" id="F25469258"><span class="drugH1">Use: Off-Label: Adult</span><p>Free-living ameba infection</p></div>
<div class="block mst drugH1Div" id="F56412954"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F23358804"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F23358801"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F49308264"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation. Patients who may become pregnant should use effective contraception during therapy and for 5 months after the last dose of miltefosine. If oral contraceptives are used and nausea, vomiting, and/or diarrhea occur during therapy, additional nonhormonal or alternative methods of effective contraception should be used.</p>
<p style="text-indent:0em;margin-top:2em;">Miltefosine may reduce ejaculate volume, total sperm count, sperm concentration, sperm morphology, and sperm motility, resulting in impaired fertility. Duration of adverse events is unknown. However, improvements of most parameters occurred within 3 to 6 months following the last miltefosine dose.</p></div>
<div class="block pri drugH1Div" id="F24249401"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to miltefosine may cause fetal harm. Embryo-fetal toxicity was observed in animal studies with doses less than the maximum recommended human dose. Use is contraindicated in pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Leishmaniasis is also associated with adverse pregnancy outcomes. Untreated visceral leishmaniasis may be life-threatening to the mother and may result in adverse fetal outcomes (eg, spontaneous abortion, congenital disease due to vertical transmission, small for gestational age newborn, severe anemia); untreated cutaneous leishmaniasis may manifest with larger and atypical appearing lesions and may be associated with adverse fetal outcomes (eg, preterm births, stillbirths).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than miltefosine are recommended for the treatment of leishmaniasis during pregnancy (Fontenele e Silva 2013; IDSA/ASTMH [Aronson 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to miltefosine is ongoing. Health care providers are encouraged to enroll patients exposed to miltefosine during pregnancy in the pregnancy registry (1-866-588-5405).</p></div>
<div class="block brc drugH1Div" id="F24249403"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if miltefosine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Agents other than miltefosine are recommended for the treatment of leishmaniasis in breastfeeding patients (Fontenele e Silva 2013; IDSA/ASTMH [Aronson 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is not recommended by the manufacturer during treatment and for 5 months after the last miltefosine dose.</p></div>
<div class="block mop drugH1Div" id="F22904238"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline and as clinically indicated during therapy: liver function tests (AST, ALT, alkaline phosphatase, bilirubin) and BUN/serum creatinine; platelet count.</p>
<p style="text-indent:-2em;margin-left:2em;">Evaluate pregnancy status prior to use in patients who may become pregnant.</p></div>
<div class="block pha drugH1Div" id="F22903474"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Exact mechanism unknown; likely interaction with phospholipids and steroids in parasitic cell membranes, inhibition of cytochrome c oxidase (mitochondrial function), and apoptosis-like cell death.</p></div>
<div class="block phk drugH1Div" id="F22903476"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; phospholipase D-like cleavage of miltefosine releases choline. Fatty alcohol-containing fragment may be oxidized to palmitic acid and undergo fatty acid metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: t<sub>½</sub> alpha: &gt;6 days; t<sub>½</sub> beta: ~31 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 4 to 7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;0.2% as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23671518"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Antylex | Impavido</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Impavido</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Impavido</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Impavido</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Impavido</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Impavido</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Leish | Miltefo | Visral</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Impavido</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Impavido</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29799869">
<a name="29799869"></a>Abongomera C, Diro E, de Lima Pereira A, et al. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: a retrospective cohort study. <i>PLoS Negl Trop Dis</i>. 2018;12(5):e0006527. doi:10.1371/journal.pntd.0006527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/29799869/pubmed" id="29799869" target="_blank">29799869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18976559">
<a name="18976559"></a>Aichelburg AC, Walochnik J, Assadian O, et al. Successful treatment of disseminated Acanthamoeba sp infection with miltefosine. <i>Emerg Infect Dis</i>. 2008;14:1743-1746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/18976559/pubmed" id="18976559" target="_blank">18976559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941143">
<a name="27941143"></a>Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). <i>Clin Infect Dis</i>. 2016;63(12):1539-1557. doi:10.1093/cid/ciw742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/27941143/pubmed" id="27941143" target="_blank">27941143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35147680">
<a name="35147680"></a>Burza S, Mahajan R, Kazmi S, et al. AmBisome monotherapy and combination AmBisome-miltefosine therapy for the treatment of visceral leishmaniasis in patients coinfected with human immunodeficiency virus in India: a randomized open-label, parallel-arm, phase 3 trial. <i>Clin Infect Dis</i>. 2022;75(8):1423-1432. doi:10.1093/cid/ciac127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/35147680/pubmed" id="35147680" target="_blank">35147680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Leishmaniasis- Resources for Health Professionals. <a href="https://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx-vl" target="_blank">http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx-vl</a>. Updated March 20, 2014. Accessed April 4, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC); Parasites - <i>Balamuthia mandrillaris</i> - Granulomatous amebic encephalitis (GAE). <a href="https://www.cdc.gov/parasites/balamuthia/treatment.html" target="_blank">https://www.cdc.gov/parasites/balamuthia/treatment.html</a>. Updated September 2019a. Accessed October 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC); Parasites - <i>Naegleria fowleri - </i>Primary amebic meningoencephalitis (PAM) - Amebic encephalitis. <a href="https://www.cdc.gov/parasites/naegleria/treatment-hcp.html" target="_blank">https://www.cdc.gov/parasites/naegleria/treatment-hcp.html</a>. Updated April 2019b. Accessed October 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679626">
<a name="26679626"></a>Cope JR, Conrad DA, Cohen N, et al. Use of the novel therapeutic agent miltefosine for the treatment of primary amebic meningoencephalitis: report of 1 fatal and 1 surviving case. <i>Clin Infect Dis</i>. 2016;62(6):774-776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/26679626/pubmed" id="26679626" target="_blank">26679626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30653490">
<a name="30653490"></a>Diro E, Blesson S, Edwards T, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. <i>PLoS Negl Trop Dis</i>. 2019;13(1):e0006988. doi:10.1371/journal.pntd.0006988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/30653490/pubmed" id="30653490" target="_blank">30653490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22585212">
<a name="22585212"></a>Dorlo TP, Huitema ADR, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. <i>Antimicrob Agents Chemother</i>. 2012;56(7):3864-3872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/22585212/pubmed" id="22585212" target="_blank">22585212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drugs.1">
<a name="Drugs.1"></a>Drugs for parasitic infections. <i>Med Lett Drugs Ther.</i> 2013;11(suppl):e1-e31.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24474006">
<a name="24474006"></a>Fontenele e Silva JS, Galvao TF, Pereira MG, Silva MT. Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence. <i>Rev Soc Bras Med Trop</i>. 2013;46(6):669-677. doi:10.1590/0037-8682-0104-2013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/24474006/pubmed" id="24474006" target="_blank">24474006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Impavido.1">
<a name="Impavido.1"></a>Impavido (miltefosine) [prescribing information]. Orlando, FL: Profounda Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25667249">
<a name="25667249"></a>Linam WM, Ahmed M, Cope JR, et al. Successful treatment of an adolescent with <i>Naegleria fowleri</i> primary amebic meningoencephalitis. <i>Pediatrics</i>. 2015;135(3):e744-e748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/25667249/pubmed" id="25667249" target="_blank">25667249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26129756">
<a name="26129756"></a>Mahajan R, Das P, Isaakidis P, et al. Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India. <i>Clin Infect Dis</i>. 2015;61(8):1255-1262. doi:10.1093/cid/civ530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/26129756/pubmed" id="26129756" target="_blank">26129756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20550438">
<a name="20550438"></a>Martínez DY, Seas C, Bravo F, Legua P, Ramos C, Cabello AM, Gotuzzo E. Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. <i>Clin Infect Dis</i>. 2010;51(2):e7-e11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/20550438/pubmed" id="20550438" target="_blank">20550438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15127339">
<a name="15127339"></a>Soto J, Arana A, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. <i>Clin Infect Dis</i>. 2004;38(9):1266-1272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/15127339/pubmed" id="15127339" target="_blank">15127339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12456849">
<a name="12456849"></a>Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. <i>N Engl J Med</i>. 2002;347(22):1739-1746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/12456849/pubmed" id="12456849" target="_blank">12456849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention (CDC); National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed July 31, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/leishmaniasis?view=ful" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/leishmaniasis?view=ful</a>. Updated October 13, 2021. Accessed January 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22869634">
<a name="22869634"></a>Webster D, Umar I, Kolyvas G, et al. Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier. <i>Am J Trop Med Hyg</i>. 2012;87(4):715-718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/miltefosine-drug-information/abstract-text/22869634/pubmed" id="22869634" target="_blank">22869634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. https://www.who.int/publications/i/item/9789240048294. Published June 7, 2022. Accessed September 27, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 91793 Version 105.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
